Skip to main content
Premium Trial:

Request an Annual Quote

People in the News

Ansa Biotechnologies: Jason Gammack and Dan Lin-Arlow

Ansa Biotechnologies has appointed Jason Gammack as CEO. Founding CEO Dan Lin-Arlow will remain with the company and transition to a new position as chief scientific officer.

Gammack brings more than 30 years of life sciences industry experience. Most recently, he cofounded and was CEO of Resolve Biosciences, a multiplex spatial analysis firm. Prior to that, he was chief commercial officer at Inscripta. He has also held leadership positions at Qiagen, Ingenuity Systems, Sigma-Aldrich, Invitrogen/Life Technologies, Affymetrix, and Promega.

BostonGene: Joe Lennerz, Mark Hiatt, Ned Segal

BostonGene appointed Joe Lennerz as CSO, Mark Hiatt as senior VP of market access and strategy, and Ned Segal as a member of the board of directors. 

Lennerz previously served as associate chief of pathology and medical director of the Center for Integrated Diagnostics at Massachusetts General Hospital and Harvard Medical School. Hiatt previously served as VP of medical affairs for Guardant Health, executive medical director for Regence BlueCross BlueShield, and chief medical officer for HealthHelp. Segal has previously served as CFO of Twitter, senior VP of finance at Intuit's Small Business Group, and as CFO at patent risk management company RPX. He most recently served as managing director and head of global software investment banking at Goldman Sachs and is a board member at RingCentral and Beyond Meat.

Ansa Biotechnologies: Jason Gammack, Dan Li-Arlow

Jason Gammack has been appointed as CEO of Ansa Biotechnologies, replacing Dan Lin-Arlow, the firm's founder, who will stay on as CSO. Gammack joins the Emeryville, California-based DNA synthesis company from Resolve Biosciences, which he cofounded and where he was CEO. Before that, he was chief commercial officer of Inscripta, and prior to that, VP of the life science business at Qiagen. He also previously held senior leadership positions at Ingenuity Systems, Sigma-Aldrich, Invitrogen (later Life Technologies), Affymetrix, and Promega.

Agilent Technologies: Mike McMullen, Padraig McDonnell

Agilent Technologies' board of directors said that the company's CEO of nine years, Mike McMullen, is stepping down from that role on May 1, and he will become an adviser to the company until his retirement begins Oct. 31. He will be succeeded by Padraig McDonnell, who is currently the president of the Agilent CrossLab Group and the company's chief commercial officer. McMullen joined Agilent's predecessor company Hewlett-Packard in 1984 and rose through senior management positions until he took over as CEO from William Sullivan in March 2015. McDonnell also joined Agilent through Hewlett-Packard, which he began working for in 1998. He has been the president of the Agilent CrossLab Group since May 2020 and chief commercial officer since November 2021.

Angelica Riemann, vice president and general manager of the Agilent CrossLab Group's CrossLab Services Division, will take over as the group's president. Jonah Kirkwood, vice president of global sales, will take over as chief commercial officer and lead the One Agilent Commercial Organization.

Cue Health: Rishi Reddy

Cue Health has appointed Rishi Reddy to its board of directors. Reddy is a managing director at Tarsadia Investments, leading the venture and growth equity strategy. Reddy was previously an observer on Cue’s board from April 2018 to September 2021. Tarsadia is Cue's largest shareholder and has expressed concern about the direction of the company and its financial performance.

Before Tarsadia, Reddy was the founder and CEO of digital pathology firm DigiPath Solutions. 

Cue said it also expects to add an independent director to the board.

Molecular Assemblies: David Smoller and Stephen Turner

Enzymatic DNA synthesis company Molecular Assemblies has named David Smoller and Stephen Turner to its commercial-technology advisory board.

Smoller is a general partner of Cultivation Capital Life Sciences Fund, a venture fund focused on life science investing. He also serves as an entrepreneur in residence at St. Louis BioGenerator, the investment arm of BioSTL. He has also held leadership roles at Sigma-Aldrich and Genome Systems, and cofounded Solis Agrosciences, Panome Bio, and Canopy Biosciences (acquired by Bruker Corporation). His earlier ventures include Sage Labs (acquired by Horizon Discovery) and ProteoPlex.

Turner founded Pacific Biosciences and was a member of the project team at Cornell University that developed the technology now used by PacBio in its sequencers. He is the author of more than 300 scientific papers in fields such as DNA sequencing technology, biophysics, genomics, and epigenomics, and is listed as the inventor on more than 50 US patents and numerous published patent applications.

TATAA Biocenter: Fabienne Deckert

TATAA Biocenter has appointed Fabienne Deckert to its scientific advisory board. Deckert has more than 30 years of experience in the pharmaceutical industry and is currently a managing director at Complyomics Sarl, according to her LinkedIn profile. She has also worked in various regulatory and research roles at the Novartis Institutes for Biomedical Research and Novartis Pharma. Deckert holds a PhD in experimental and clinical pharmacology.

ASHG: Amanda Perl

The American Society of Human Genetics has named Amanda Perl as its next CEO, effective May 14. Perl joins ASHG from the American Thyroid Association, where she served as executive director. Prior to that, Perl was the chief global member engagement officer at the Endocrine Society, where she led the creation of the society's first special interest groups to increase member engagement and value. Prior to that, Perl spent nine years with the Institute of Food Technologists. She holds a bachelor's degree in interdisciplinary studies and public communication from American University in Washington, DC.

MDxHealth: Jan Pensaert

Jan Pensaert has resigned from MDxHealth's board of directors, effective Feb. 15. His resignation is not due to any disagreement with MDxHealth's operations, policies, or practices, the firm said. Pensaert is the founding managing partner of UK-based asset management company Valiance. He was also the CEO of La Fayette, whose assets under management grew to $5.5 billion from $750 million during his tenure, according to MDxHealth's website.

Myriad Genetics: Dallas Reed

Myriad Genetics appointed Dallas Reed as principal medical advisor to its women's health business unit, effective immediately. Reed is an Ob/Gyn and medical geneticist who serves as the chief of genetics at Tufts Medical Center and as an associate professor at Tufts University School of Medicine. She also serves as a board member for the Boston Market of the March of Dimes. She holds an MD from Boston University School of Medicine and a BS in biology from Dillard University.